{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:31:53Z","timestamp":1787772713988,"version":"build-2784847793"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Patients with chronic bullous disease of childhood (CBDC) generally respond well to treatment with drugs like Dapsone and oral and topical steroids. Refractory cases are additionally treated with immunosuppressants like azathioprine, methotrexate, ciclosporin, colchicine, tetracycline, and IVIG (Intravenous Immunoglobulin). However, there are few patients who fail to respond to these therapies and pose a challenge both to the patient and the treating physician. Rituximab has been used widely to treat pemphigus cases in adults, but its use in children has not been much reported. We hereby report a case of a 5-year-old child with CBDC, refractory to other treatments, who responded favorably to Rituximab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/idoj.idoj_914_20","type":"journal-article","created":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T11:01:13Z","timestamp":1637492473000},"page":"900-903","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of a Refractory Case of Chronic Bullous Disease of Childhood in a Five Year Old Child with Rituximab"],"prefix":"10.4103","volume":"12","author":[{"given":"Uma S.","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet K.","family":"Randhawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20240828","first-page":"151","article-title":"Chronic bullous disease or linear IgA dermatosis of childhood -Revisited","volume":"4","author":"Patsatsi","year":"2013","journal-title":"J Genet Syndr Gene Ther"},{"key":"R2-18-20240828","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archderm.143.8.1033","article-title":"Treatment of severe pemphigus with rituximab: Report of 12 cases and a review of the literature","volume":"143","author":"Cianchini","year":"2007","journal-title":"Arch Dermatol"},{"key":"R3-18-20240828","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1525-1470.2005.00118.x","article-title":"Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab)","volume":"22","author":"Kong","year":"2005","journal-title":"Pediatr Dermatol"},{"key":"R4-18-20240828","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4103\/ijdd.ijdd_31_17","article-title":"Rituximab in the treatment of skin diseases","volume":"3","author":"Rajagopalan","year":"2017","journal-title":"Indian J Drugs Dermatol"},{"key":"R5-18-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/pde.13926","article-title":"Rituximab therapy in pediatric pemphigus patients: A retrospective analysis of five Turkish patients and review of the literature","volume":"36","author":"Bilgic-Temel","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"R6-18-20240828","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4103\/2319-7250.175664","article-title":"Successful treatment of refractory childhood vesiculobullous disorders with rituximab: A study of five cases","volume":"17","author":"Buch","year":"2016","journal-title":"Indian J Paediatr Dermatol"},{"key":"R7-18-20240828","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4103\/0378-6323.102354","article-title":"Rituximab in pemphigus","volume":"78","author":"Kanwar","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R8-18-20240828","doi-asserted-by":"crossref","first-page":"632","DOI":"10.4103\/0378-6323.100587","article-title":"Childhood pemphigus vulgaris successfully treated with rituximab","volume":"78","author":"Kanwar","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R9-18-20240828","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1525-1470.2007.00369.x","article-title":"Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment","volume":"24","author":"Connelly","year":"2007","journal-title":"Pediatr Dermatol"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.IDOJ_914_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:10:10Z","timestamp":1787771410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.IDOJ_914_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_914_20","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}